Research graph
References from Osimertinib plus Gefitinib in Patients with EGFR -Mutated Advanced Non–Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD. Local targets link to admitted publications; unresolved targets remain external evidence.
Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer
10.1056/nejmoa1713137 · 2018 · External reference
Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC
10.1056/nejmoa1913662 · 2020 · External reference
AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer
10.1158/2159-8290.cd-14-0337 · 2014 · External reference
CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer
10.1200/jco.2018.78.3118 · 2018 · External reference
Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC
10.1056/nejmoa2306434 · 2023 · External reference
Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer
10.1056/nejmoa1612674 · 2017 · External reference
CNS efficacy of osimertinib in patients with T790M-positive advanced non–small-cell lung cancer: data from a randomized phase III trial (AURA3)
10.1200/jco.2018.77.9363 · 2018 · External reference
Therapy for stage IV non-small cell lung cancer with driver alterations: ASCO living guideline, version 2025.1
10.1200/jco-25-01061 · 2025 · External reference
Updated treatment recommendations for systemic treatment: from the ESMO oncogene-addicted metastatic NSCLC living guideline
10.1016/j.annonc.2025.06.007 · 2025 · External reference
Optimizing osimertinib for NSCLC: targeting resistance and exploring combination therapeutics
10.3390/cancers17030459 · 2025 · External reference
Possibilities of overcoming resistance to osimertinib in NSCLC patients with mutations in the EGFR gene
10.3390/cancers17040563 · 2025 · External reference
Strategies to overcome resistance to osimertinib in EGFR-mutated lung cancer
10.3390/ijms26072957 · 2025 · External reference
FDA grants accelerated approval to datopotamab deruxtecan-dlnk for EGFR-mutated non-small cell lung cancer
2025 · External reference
MA12.03 FLAURA2: resistance, and impact of baseline TP53 alterations in patients treated with 1L osimertinib ± platinum-pemetrexed
10.1016/j.jtho.2024.09.184 · 2024 · External reference
Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer
10.1038/s41467-023-35961-y · 2023 · External reference
Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients
10.1158/1078-0432.ccr-17-2310 · 2018 · External reference
First-line osimertinib in patients with EGFR-mutated non-small cell lung cancer: effectiveness, resistance mechanisms, and prognosis of different subsequent treatments
10.1177/11795549221134735 · 2022 · External reference
Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial
10.1038/s41467-023-35962-x · 2023 · External reference
Genomic profiling of epidermal growth factor receptor mutation-positive non-small cell lung cancer post-progression on first-line osimertinib: phase II ORCHARD study
10.1158/1078-0432.ccr-25-4540 · 2026 · External reference
ELIOS: a multicenter, molecular profiling study of patients with EGFR-mutant advanced non-small cell lung cancer treated with first-line osimertinib
10.1158/2159-8290.cd-25-0960 · 2026 · External reference
Advancements in fourth-generation EGFR TKI in EGFR-mutant NSCLC: bridging biological insights and therapeutic development
10.1016/j.ctrv.2024.102824 · 2024 · External reference
Next-generation EGFR tyrosine kinase inhibitors to overcome C797S mutation in non-small cell lung cancer (2019-2024)
10.1039/d4md00384e · 2024 · External reference
Fourth-generation EGFR-TKI to overcome C797S mutation: past, present, and future
10.1080/14756366.2025.2481392 · 2025 · External reference
The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies
10.1158/1078-0432.ccr-15-0560 · 2015 · External reference
EGFR mutations and resistance to irreversible pyrimidine-based EGFR inhibitors
10.1158/1078-0432.ccr-14-2789 · 2015 · External reference
EGFR-mutated lung cancers resistant to osimertinib through EGFR C797S respond to first-generation reversible EGFR inhibitors but eventually acquire EGFR T790M/C797S in preclinical models and clinical samples
10.1016/j.jtho.2019.07.016 · 2019 · External reference
Preclinical comparison of osimertinib with other EGFR-TKI in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity
10.1158/1078-0432.ccr-16-0399 · 2016 · External reference
A PET study in healthy subjects of brain exposure of 11C-labelled osimertinib - a drug intended for treatment of brain metastases in non-small cell lung cancer
10.1177/0271678x19843776 · 2020 · External reference
Brain exposure of osimertinib in patients with epidermal growth factor receptor mutation non-small cell lung cancer and brain metastases: a positron emission tomography and magnetic resonance imaging study
10.1111/cts.13500 · 2023 · External reference
Preclinical comparison of the blood-brain barrier permeability of osimertinib with other EGFR TKI
10.1158/1078-0432.ccr-19-1871 · 2021 · External reference
Biomarker-directed phase II platform study in patients with EGFR sensitizing mutation-positive advanced/metastatic non-small cell lung cancer whose disease has progressed on first-line osimertinib therapy (ORCHARD)
10.1016/j.cllc.2021.06.006 · 2021 · External reference
Decision-making in early clinical drug development
10.1002/pst.1746 · 2016 · External reference
Real-world analysis of subsequent-line strategies for EGFR C797S mutant non-small cell lung cancer patients acquired resistance to third-generation EGFR tyrosine kinase inhibitors
10.1186/s12885-025-15335-x · 2025 · External reference
Effective clinical response of lung adenocarcinoma harboring EGFR 19Del/T790M/in cis-C797S osimertinib to osimertinib and gefitinib combination therapy
10.21037/qims-22-1269 · 2023 · External reference
Combination osimertinib and gefitinib in C797S and T790M EGFR-mutated non-small cell lung cancer
10.1016/j.jtho.2017.08.006 · 2017 · External reference
Lung adenocarcinoma Harboring EGFR T790M and in trans C797S responds to combination therapy of first- and third-generation EGFR TKI and shifts allelic configuration at resistance
10.1016/j.jtho.2017.06.017 · 2017 · External reference
Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis
10.1016/j.annonc.2020.08.2100 · 2020 · External reference
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study
10.1016/j.annonc.2023.10.117 · 2024 · External reference
Tagrisso (osimertinib) [Highlights of prescribing information]
2024 · External reference
Iressa (gefitinib) [Highlights of prescribing information]
2023 · External reference
Unraveling the impact of intratumoral heterogeneity on EGFR tyrosine kinase inhibitor resistance in EGFR-mutated NSCLC
10.3390/ijms24044126 · 2023 · External reference
Research progress on the role of bypass activation mechanisms in resistance to tyrosine kinase inhibitors in non-small cell lung cancer
10.3389/fonc.2024.1447678 · 2024 · External reference
Concurrent osimertinib plus gefitinib for first-line treatment of EGFR-mutated non-small cell lung cancer (NSCLC)
10.1200/jco.2020.38.15_suppl.9507 · 2020 · External reference
A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATE
10.1038/s41467-024-46008-1 · 2024 · External reference
